title: The impact and desirability of news of risk for schizophrenia.
abstract: In studies of schizotypy, investigators seldom inform participants that they are engaged in research designed to shed light on risk for schizophrenia. Such nondisclosure is justified in part by the argument that disclosure of risk status may be harmful. However, there is little evidence that this is the case. Harm arising from disclosure of risk status was examined in two experiments. In the first, participants (n = 114 psychology undergraduates) were asked to anticipate their reactions to news of risk for schizophrenia, depression, cancer, and diabetes, and also to indicate whether they would want to know their schizophrenia risk status. Participants anticipated schizophrenia risk would have a negative impact that was significantly greater than depression or diabetes risk but similar to cancer risk. The anticipated impact of schizophrenia risk was predicted by expectations of stigmatization as well as confidence in the accuracy of biological screening. Although 81% indicated a preference for knowing their risk status, just 11% were prepared to undergo an assessment to find out. In the second, a between-subjects deception paradigm was used to inform participants (n = 144 psychology undergraduates) they had an enzyme deficiency that placed them at increased risk for schizophrenia, cancer, or depression. Impact was assessed using prospective self-report and salivary cortisol and retrospective self-report. Impact was modeled using measures of stigmatization and health locus of control. Retrospectively, schizophrenia, cancer, and depression risk had strong negative impacts relative to a control group, but there was no effect on prospective measures. Together, the findings suggest that news of risk for schizophrenia has the potential to engender distress, although participants' anticipations and reflections of responses are not corroborated in prospectively measured outcomes.
authors: Department of Psychology, University of Otago, Dunedin, New Zealand.
authors: Roni G
authors: RG
authors: Alder
authors: Jennifer L
authors: JL
authors: Young
authors: Elizabeth I
authors: EI
authors: Russell
authors: Danielle R
authors: DR
authors: McHardy
authors: Richard J
authors: RJ
authors: Linscott
mesh_terms: D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008297:Male; D010465:Perception; D011594:Psychometrics; D012044:Regression Analysis; D012189:Retrospective Studies; D012306:Risk; D012559:Schizophrenia / Q000175:diagnosis; D012565:Schizophrenic Psychology; D012680:Sensitivity and Specificity; D055815:Young Adult
references: J Steroid Biochem. 1985 May;22(5):673-6
references: 4010291
references: J Pers Soc Psychol. 1999 Jan;76(1):114-28
references: 9972557
references: J Pers Disord. 2007 Jun;21(3):225-42
references: 17536937
references: Psychosom Med. 1996 Sep-Oct;58(5):447-58
references: 8902896
references: Soc Psychiatry Psychiatr Epidemiol. 2004 Jan;39(1):73-7
references: 15022050
references: Soc Sci Med. 1999 Dec;49(12):1571-98
references: 10574231
references: J Steroid Biochem. 1985 Mar;22(3):387-90
references: 3990288
references: Can J Psychiatry. 2001 Apr;46(3):245-52
references: 11320678
references: Steroids. 1992 Feb;57(2):82-5
references: 1621261
references: Schizophr Res. 2005 Mar 1;73(2-3):173-84
references: 15653260
references: Am Psychol. 1996 Dec;51(12):1213-30
references: 8962530
references: Am J Hum Genet. 1999 May;64(5):1293-304
references: 10205260
references: Psychol Med. 2013 Jun;43(6):1133-49
references: 22850401
references: Psychiatry Res. 2009 Apr 30;166(2-3):184-91
references: 19285732
references: Psychoneuroendocrinology. 2009 May;34(4):607-14
references: 19059727
references: Biol Psychol. 2007 Jan;74(1):104-7
references: 16904811
references: Eur J Hum Genet. 2000 Oct;8(10):731-8
references: 11039571
references: Adv Physiol Educ. 2007 Mar;31(1):110-5
references: 17327591
references: Soc Psychiatry Psychiatr Epidemiol. 2003 Jun;38(6):311-6
references: 12799781
references: Psychoneuroendocrinology. 2004 Sep;29(8):983-92
references: 15219648
references: Clin Chim Acta. 1986 Sep 15;159(2):205-9
references: 3769209
references: J Clin Endocrinol Metab. 2007 Mar;92(3):819-24
references: 17179195
references: Psychoneuroendocrinology. 2003 Jan;28(1):35-47
references: 12445835
references: Acta Psychiatr Scand. 2003 Oct;108(4):304-9
references: 12956832
references: Pharmacol Biochem Behav. 2006 Mar;83(3):441-7
references: 16631247
references: Chronobiol Int. 2003 Sep;20(5):863-78
references: 14535359
references: Schizophr Res. 2006 Jun;84(2-3):289-96
references: 16542824
references: J Behav Med. 1990 Feb;13(1):31-52
references: 2189997
references: Annu Rev Psychol. 2001;52:27-58
references: 11148298
references: Psychopharmacology (Berl). 1982;78(4):305-8
references: 6818588
references: Schizophr Bull. 1999;25(3):437-46
references: 10478779
references: Psychol Bull. 2004 May;130(3):355-91
references: 15122924
references: J Health Psychol. 2005 Sep;10(5):623-31
references: 16033784
references: Sleep. 1997 Oct;20(10):865-70
references: 9415946
references: Psychol Sci. 2002 Jan;13(1):85-8
references: 11892785
references: J Consult Clin Psychol. 1996 Dec;64(6):1387-96
references: 8991325
references: Schizophr Bull. 2001;27(2):187-95
references: 11354586
references: Health Educ Monogr. 1978 Spring;6(2):160-70
references: 689890
references: Dialogues Clin Neurosci. 2005;7(1):53-67
references: 16060596